600056 中国医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)2.4754.5399.3686.982--
总资产报酬率 ROA (%)0.8051.4522.8592.196--
投入资产回报率 ROIC (%)1.2762.3344.7343.594--

边际利润分析
销售毛利率 (%)10.43410.71411.29112.62714.396
营业利润率 (%)3.0742.7284.3073.1912.586
息税前利润/营业总收入 (%)2.9923.3654.5143.5503.206
净利润/营业总收入 (%)2.1982.0113.1992.3631.971

收益指标分析
经营活动净收益/利润总额(%)122.442122.21280.615121.618186.516
价值变动净收益/利润总额(%)2.9476.552-0.9034.4254.417
营业外收支净额/利润总额(%)-0.7972.268-1.937-0.2990.316

偿债能力分析
流动比率 (X)1.4161.5231.5841.495--
速动比率 (X)1.0981.1741.2381.158--
资产负债率 (%)61.51760.55262.87763.312--
带息债务/全部投入资本 (%)38.95137.75135.64538.609--
股东权益/带息债务 (%)131.868137.092143.241129.484--
股东权益/负债合计 (%)51.91154.70449.14747.581--
利息保障倍数 (X)-52.2685.86515.6439.6485.241

营运能力分析
应收账款周转天数 (天)146.419141.571125.141116.4460.000
存货周转天数 (天)73.75573.89864.36664.3380.000